Nucala 100 MG/ML powder vials
Ended Awarded
- Contract number
- SPE2DB25FX2AU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,530
Award facts
- Contract value 100% obligated
- $19,529.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $19,529.90 by the Defense Logistics Agency on July 31, 2025, for the supply of NUCALA 100 mg/ml powder vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and does not utilize a set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products to support Department of Defense healthcare facilities worldwide.
NUCALA (mepolizumab) is a biologic medication used in the treatment of severe eosinophilic asthma and other eosinophilic conditions. The delivery order reflects DMS Pharmaceutical Group's established role as a critical supplier in the federal pharmaceutical supply chain, providing branded and generic prescription drugs, biologics, and specialized medications directly to military health facilities. The company's consistent success in securing federal contracts without specific set-aside designations demonstrates its competitive positioning within federal procurement markets, supported by its woman-owned small business status and extensive experience serving Defense Department healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FX2AU?
SPE2DB25FX2AU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 31, 2025.
How much is contract SPE2DB25FX2AU worth?
The government has obligated $19,530 on SPE2DB25FX2AU.
Is contract SPE2DB25FX2AU an order under another contract?
Yes. SPE2DB25FX2AU is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB25FX2AU competed?
The extent of competition for SPE2DB25FX2AU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award